Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05883033
Other study ID # Necrotizing fasciitis
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2023
Est. completion date April 30, 2024

Study information

Verified date May 2023
Source Assiut University
Contact Mario Saba, BMMS
Phone +201091196224
Email mario_saba_417@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Find out the best management of Necrotizing Fasciitis after surgical debridement


Description:

Necrotizing fasciitis is a life-threatening condition that can occur as a result of trauma or foreign bodies in surgical wounds as well as idiopathically. Necrotizing fasciitis is characterized by a progressive infection in fascial planes with necrosis of the subcutaneous tissue. Necrotizing fasciitis affects the extremities more frequently than central areas. Risk factors for necrotizing fasciitis include diabetes mellitus, trauma wound infections, decubitus ulcers, alcoholism, carcinoma, peripheral vascular disease, smoking, and intravenous drug abuse. A varieties of micro-organisms, including gram-positive group A streptococcus, haemolytic streptococci, and staphylococcus aureus; gram-negative Enterobacteriaceae, Escherichia coli, Klebsiella spp., and Proteus spp.; anaerobes including Peptostreptococcus, Clostridium, and Pacteroides; and fungi such as Candida and acid-fast bacteria have all been implicated in the pathogenesis of Necrotizing fasciitis. Necrotizing fasciitis is a surgical emergency for detoxification by debridement with good antibiotic coverage. It has mortality rate reaching 20-30% , this mortality rate is high and requires prompt diagnosis, antibiotic treatment and extensive necrosectomy up to intensive care units admission in some cases, the aim of our prospective analysis is to assess with a hypothesis-generating and exploratory purpose the possible role of VAC versus ordinary dressings in the wound therapy of Necrotizing Fasciitis in terms of expected time for wound closure and survival rate.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date April 30, 2024
Est. primary completion date April 1, 2024
Accepts healthy volunteers No
Gender All
Age group 1 Year and older
Eligibility Inclusion Criteria: - Immunocompromised patients such as; diabetic, HIV and leukaemia. And other chronic debilitating diseases. Exclusion Criteria: - Necrotizing Fasciitis of Head and neck and upper limbs.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
VAC
Vacuum Assisted Closure device

Locations

Country Name City State
Egypt Assiut University Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Zhang R, Zhang Y, Hou L, Yan C. Vacuum-assisted closure versus conventional dressing in necrotizing fasciitis: a systematic review and meta-analysis. J Orthop Surg Res. 2023 Feb 4;18(1):85. doi: 10.1186/s13018-023-03561-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Hospital staying length the difference in hospital stay length between patients with necrotizing fasciitis who received conventional management versus those treated with vacuum-assisted closure. A systematic review showed a significant difference between the two methods Baseline
Secondary Required other stages of debridement Comparison in the other stages of debridement required in both methods Baseline
Secondary Expected closure of the wound by secondary intention The difference in expected time required for closure of the wound by secondary intention between patients with necrotizing fasciitis who received conventional management versus those treated with vacuum-assisted closure. Baseline
See also
  Status Clinical Trial Phase
Completed NCT04831112 - Compare Effects of Dressing With Honey and EUSOL N/A
Completed NCT03147352 - Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study
Completed NCT06249971 - A Single-stage Bilayered Skin Reconstruction With Glyaderm® N/A